Tuesday, February 09, 2021, 02:00pm - 03:00pm
|
|
|
|
INSIDE INNOVATION E-TALKS PRESENTS
|
|
|
Understanding Biologics and the COVID-19 Vaccine
|
Did you know that the COVID-19 vaccine's origins were developed right here on the Forty Acres? Join some of UT's top experts as they explain the basics of biologic drugs, offer insight into how the COVID-19 vaccines were created and share exciting plans about UT's future in disease prevention and treatment.
|
|
|
Tuesday, February 9
2–3 PM (CST)
|
|
|
|
|
|
F E A T U R I N G
|
|
|
|
|
Steven McKnight (Moderator)
Steve McKnight (B.A. Biology 1974) began working at the Carnegie Institution of Washington in 1983 and was later appointed as a Howard Hughes Medical Institute investigator in 1988. His research focused on gene regulation, using molecular biological methods to define the regulatory DNA sequences constituting the promoter of the herpes simplex virus thymidine kinase gene. McKnight left academia in 1991 to co-found Tularik, a San Francisco-based biotechnology company devoted to the discovery of ethical drugs. He moved to UT Southwestern in 1995, where he was appointed chair of the Department of Biochemistry in 1996. He is a member of the National Academy of Sciences, the Institute of Medicine and the American Academy of Arts and Sciences.
|
|
|
|
|
|
|
|
George Georgiou
George Georgiou is a professor in the Cockrell School of Engineering’s McKetta Department of Chemical Engineering and Department of Biomedical Engineering, as well as the College of Natural Science’s Department of Molecular Biosciences. He is one of the world’s most prominent researchers in antibody and enzyme therapeutics and the molecular analysis of human antibody immunity, and he is the co-inventor of over 135 patents that have been licensed to 31 pharmaceutical and biotechnology companies. As an entrepreneur, Georgiou founded GGMJD, Aeglea Biotherapeutics (NSDQ: AGLE) and Ikena Oncology. Nature Biotechnology named him one of the world’s top 20 translational researchers, and he is a member of both the National Academy of Medicine and National Academy of Engineering.
|
|
|
|
|
|
|
|
Jennifer Maynard
Jennifer Maynard (Ph.D. ChE 2002) is a professor in the Cockrell School’s McKetta Department of Chemical Engineering. She specializes in vaccines, T cells and biologics, and she co-developed the commercial inhalation anthrax treatment, Anthim, with George Georgiou. Maynard is a recipient of the Bill and Melinda Gates Foundation’s Grand Challenge Award, is a Packard Fellow and received the inaugural UT Austin “Emerging Inventor of the Year” award in 2015 for her translational research.
|
|
|
|
|
|
|
|
Jason McLellan
Jason McLellan is an associate professor in the College of Natural Science’s Department of Molecular Biosciences. His groundbreaking research focuses on structural biology and vaccine development, and his laboratory pioneered the stabilized "2P" spike protein antigens used in the COVID-19 vaccines from Pfizer/BioNTech, Moderna, Johnson & Johnson and Novavax. Most recently, he received the American Association for the Advancement of Science’s 2020 Golden Goose Award and the William Prusoff Memorial Award from the International Society for Antiviral Research.
|
|
|
|
|
|
|
|
|
|
Kindly RSVP by February 8
|
|
|
|
|
|
Participants will be emailed a link to access the webinar after they RSVP.
|
|
|
|
|
|
|
|
|
Location: Zoom - register at link below to get Zoom link
